Bisphosphonate Associated Osteonecrosis of the Jaw
Authors:
- Aliya A. KhanAKAliya A. Khan
- George K.B. SándorGSGeorge K.B. Sándor
- Edward DoreEDEdward Dore
- Archibald D. MorrisonAMArchibald D. Morrison
- Mazen AlsahliMAMazen Alsahli
- Faizan AminFAFaizan Amin
- Edmund PetersEPEdmund Peters
- David A. HanleyDHDavid A. Hanley
- Sultan R. ChaudrySCSultan R. Chaudry
- Brian LentleBLBrian Lentle
- David W. DempsterDDDavid W. Dempster
- Francis H. GlorieuxFGFrancis H. Glorieux
- 13 March 2009
- journal article
- review article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 36 (3) , 478-490
Abstract
In 2003, the first reports describing osteonecrosis of the jaw (ONJ) in patients receiving bisphosphonates (BP) were published. These cases occurred in patients with cancer receiving high-dose intravenous BP; however, 5% of the cases were in patients with osteoporosis receiving low-dose bisphosphonate therapy. We present the results of a systematic review of the incidence, risk factors, diagnosis, prevention, and treatment of BP associated ONJ. We conducted a comprehensive literature search for relevant studies on BP associated ONJ in oncology and osteoporosis patients published before February 2008.All selected relevant articles were sorted by area of focus. Data for each area were abstracted by 2 independent reviewers. The results showed that the diagnosis is made clinically. Prospective data evaluating the incidence and etiologic factors are very limited. In oncology patients receiving high-dose intravenous BP, ONJ appears to be dependent on the dose and duration of therapy, with an estimated incidence of 1%–12% at 36 months of exposure. In osteoporosis patients, it is rare, with an estimated incidence < 1 case per 100,000 person-years of exposure. The incidence of ONJ in the general population is not known. Currently, there is insufficient evidence to confirm a causal link between low-dose BP use in the osteoporosis patient population and ONJ. We concluded BP associated ONJ is associated with high-dose BP therapy primarily in the oncology patient population. Prevention and treatment strategies are currently based on expert opinion and focus on maintaining good oral hygiene and conservative surgical intervention.Keywords
This publication has 72 references indexed in Scilit:
- Tooth Extraction Socket Healing in Pediatric Patients Treated with Intravenous PamidronateThe Journal of Pediatrics, 2008
- Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral ResearchJournal of Bone and Mineral Research, 2007
- Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?Bone, 2007
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 2007
- Bisphosphonate treatment as a cause of jaw osteonecrosisOral Diseases, 2007
- Double-Stranded RNA-Dependent Protein Kinase Is Involved in 2-Methoxyestradiol—Mediated Cell Death of Osteosarcoma CellsJournal of Bone and Mineral Research, 2007
- Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 casesInternational Journal of Oral and Maxillofacial Surgery, 2006
- Osteonecrosis of the Jaw and BisphosphonatesNew England Journal of Medicine, 2005
- Bisphosphanates and Oral Cavity Avascular Bone NecrosisJournal of Clinical Oncology, 2003
- Bone and gallium scans in postradiotherapy osteonecrosis of the jawHead & Neck, 1992